Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study

The Prostate ◽  
2016 ◽  
Vol 76 (15) ◽  
pp. 1345-1352 ◽  
Author(s):  
Alexander Nosov ◽  
Sergey Reva ◽  
Sergey Petrov ◽  
Eldar Mamijev ◽  
Roman Novikov ◽  
...  
2013 ◽  
Vol 2013 ◽  
pp. 1-7
Author(s):  
Stavros Sfoungaristos ◽  
Vasileios Kourmpetis ◽  
Eleftherios Fokaefs ◽  
Petros Perimenis

High-risk prostate cancer represents a pretentious clinical problem since a significant number of its patients will relapse and progress after radical prostatectomy. Neoadjuvant chemotherapy may be valuable since its efficacy in hormone-resistant prostate cancer has been established. In this paper, we report studies of neoadjuvant chemotherapies that have been used in high-risk patients prior to radical prostatectomy. Even though the results regarding the prognostic surrogates are not significant, the effects on clinical and pathological outcomes are promising, while toxicity in most of the studies is in the expected field.


2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 222-222 ◽  
Author(s):  
Adam S. Kibel ◽  
Joel Picus ◽  
Michael S. Cookson ◽  
Bruce Roth ◽  
David F. Jarrard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document